Eyerising International is leading the effort to control the progression of childhood Myopia with it’s world-first at-home device for Myopia control, the Myproclear. Non–invasive, and without the need for medication, eyedrops or lenses, this technology is the only one on the market suitable for children as young as 3 years of age, when beginning control can have the best long-term impact. Eyerising Internationals pioneering Repeated Low-level Red Light (RLRL) Technology, delivered via the patented Myproclear medical device, has been proven in published clinical trials to be the world's most effective Myopia treatment, dramatically reducing the progression of myopia by up to 87.7%.